TY - JOUR
T1 - Hypertension care cascades and reducing inequities in cardiovascular disease in low- and middle-income countries
AU - Stein, Dorit Talia
AU - Reitsma, Marissa B.
AU - Geldsetzer, Pascal
AU - Agoudavi, Kokou
AU - Aryal, Krishna Kumar
AU - Bahendeka, Silver
AU - Brant, Luisa C.C.
AU - Farzadfar, Farshad
AU - Gurung, Mongal Singh
AU - Guwatudde, David
AU - Houehanou, Yessito Corine Nadège
AU - Malta, Deborah Carvalho
AU - Martins, João Soares
AU - Saeedi Moghaddam, Sahar
AU - Mwangi, Kibachio Joseph
AU - Norov, Bolormaa
AU - Sturua, Lela
AU - Zhumadilov, Zhaxybay
AU - Bärnighausen, Till
AU - Davies, Justine I.
AU - Flood, David
AU - Marcus, Maja E.
AU - Theilmann, Michaela
AU - Vollmer, Sebastian
AU - Manne-Goehler, Jennifer
AU - Atun, Rifat
AU - Sudharsanan, Nikkil
AU - Verguet, Stéphane
N1 - Publisher Copyright:
© The Author(s), under exclusive licence to Springer Nature America, Inc. 2024.
PY - 2024/2
Y1 - 2024/2
N2 - Improving hypertension control in low- and middle-income countries has uncertain implications across socioeconomic groups. In this study, we simulated improvements in the hypertension care cascade and evaluated the distributional benefits across wealth quintiles in 44 low- and middle-income countries using individual-level data from nationally representative, cross-sectional surveys. We raised diagnosis (diagnosis scenario) and treatment (treatment scenario) levels for all wealth quintiles to match the best-performing country quintile and estimated the change in 10-year cardiovascular disease (CVD) risk of individuals initiated on treatment. We observed greater health benefits among bottom wealth quintiles in middle-income countries and in countries with larger baseline disparities in hypertension management. Lower-middle-income countries would see the greatest absolute benefits among the bottom quintiles under the treatment scenario (29.1 CVD cases averted per 1,000 people living with hypertension in the bottom quintile (Q1) versus 17.2 in the top quintile (Q5)), and the proportion of total CVD cases averted would be largest among the lowest quintiles in upper-middle-income countries under both diagnosis (32.0% of averted cases in Q1 versus 11.9% in Q5) and treatment (29.7% of averted cases in Q1 versus 14.0% in Q5) scenarios. Targeted improvements in hypertension diagnosis and treatment could substantially reduce socioeconomic-based inequalities in CVD burden in low- and middle-income countries.
AB - Improving hypertension control in low- and middle-income countries has uncertain implications across socioeconomic groups. In this study, we simulated improvements in the hypertension care cascade and evaluated the distributional benefits across wealth quintiles in 44 low- and middle-income countries using individual-level data from nationally representative, cross-sectional surveys. We raised diagnosis (diagnosis scenario) and treatment (treatment scenario) levels for all wealth quintiles to match the best-performing country quintile and estimated the change in 10-year cardiovascular disease (CVD) risk of individuals initiated on treatment. We observed greater health benefits among bottom wealth quintiles in middle-income countries and in countries with larger baseline disparities in hypertension management. Lower-middle-income countries would see the greatest absolute benefits among the bottom quintiles under the treatment scenario (29.1 CVD cases averted per 1,000 people living with hypertension in the bottom quintile (Q1) versus 17.2 in the top quintile (Q5)), and the proportion of total CVD cases averted would be largest among the lowest quintiles in upper-middle-income countries under both diagnosis (32.0% of averted cases in Q1 versus 11.9% in Q5) and treatment (29.7% of averted cases in Q1 versus 14.0% in Q5) scenarios. Targeted improvements in hypertension diagnosis and treatment could substantially reduce socioeconomic-based inequalities in CVD burden in low- and middle-income countries.
UR - http://www.scopus.com/inward/record.url?scp=85183154450&partnerID=8YFLogxK
U2 - 10.1038/s41591-023-02769-8
DO - 10.1038/s41591-023-02769-8
M3 - Article
AN - SCOPUS:85183154450
SN - 1078-8956
VL - 30
SP - 414
EP - 423
JO - Nature Medicine
JF - Nature Medicine
IS - 2
ER -